Cargando…

Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective

BACKGROUND: Hypoglossal nerve stimulation (HNS) with Inspire is a novel treatment indicated for moderate or severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS), intolerant to or unable to be treated with continuous positive airway pressure (CPAP). OBJECTIVE: The aim of this study was to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Blissett, Deirdre B., Steier, Joerg S., Karagama, Yakubu G., Blissett, Rob S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333158/
https://www.ncbi.nlm.nih.gov/pubmed/33913119
http://dx.doi.org/10.1007/s41669-021-00266-7
_version_ 1783732975815360512
author Blissett, Deirdre B.
Steier, Joerg S.
Karagama, Yakubu G.
Blissett, Rob S.
author_facet Blissett, Deirdre B.
Steier, Joerg S.
Karagama, Yakubu G.
Blissett, Rob S.
author_sort Blissett, Deirdre B.
collection PubMed
description BACKGROUND: Hypoglossal nerve stimulation (HNS) with Inspire is a novel treatment indicated for moderate or severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS), intolerant to or unable to be treated with continuous positive airway pressure (CPAP). OBJECTIVE: The aim of this study was to assess the cost effectiveness of treating moderate or severe OSAHS, in patients intolerant to CPAP, with HNS, compared with standard care, from a National Health Service (NHS) perspective. METHODS: A cohort state transition model was developed to compare HNS with Inspire with no treatment in UK adult patients with moderate or severe OSAHS who have previously tried and have not responded to CPAP therapy. Published literature was applied in the model to estimate incremental cost-effectiveness ratios (ICERs; 2019 Great British pounds per quality-adjusted life-year [QALY] gained), from an NHS and personal social services (PSS) perspective, over a cohort’s lifetime. RESULTS: The model base-case predicts that patients undergoing HNS will incur lifetime costs of £65,026 compared with £36,727 among untreated patients. The HNS cohort would gain 12.72 QALYs compared with 11.15 QALYs in the no-treatment arm. The ICER of treating severe OSAHS with HNS is therefore estimated to be £17,989 per QALYs gained. Probabilistic sensitivity analysis found that at a threshold of £30,000/QALY, HNS has a 69% probability of being cost effective. Limitations of the model include uncertainty around the utility data that were not sourced directly from HNS clinical trials. There is further uncertainty in the relationship between change in the Apnoea-Hypopnoea Index (AHI) and reduction in ischaemic heart disease and stroke because of difficulty capturing the reduction in risk over a long time horizon in studies. CONCLUSIONS: Over a patient’s lifetime, HNS with Inspire is expected to be cost effective when compared with no treatment in patients with severe OSAHS who have tried and have not responded to CPAP, from an NHS perspective. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00266-7.
format Online
Article
Text
id pubmed-8333158
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83331582021-08-20 Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective Blissett, Deirdre B. Steier, Joerg S. Karagama, Yakubu G. Blissett, Rob S. Pharmacoecon Open Original Research Article BACKGROUND: Hypoglossal nerve stimulation (HNS) with Inspire is a novel treatment indicated for moderate or severe obstructive sleep apnoea/hypopnoea syndrome (OSAHS), intolerant to or unable to be treated with continuous positive airway pressure (CPAP). OBJECTIVE: The aim of this study was to assess the cost effectiveness of treating moderate or severe OSAHS, in patients intolerant to CPAP, with HNS, compared with standard care, from a National Health Service (NHS) perspective. METHODS: A cohort state transition model was developed to compare HNS with Inspire with no treatment in UK adult patients with moderate or severe OSAHS who have previously tried and have not responded to CPAP therapy. Published literature was applied in the model to estimate incremental cost-effectiveness ratios (ICERs; 2019 Great British pounds per quality-adjusted life-year [QALY] gained), from an NHS and personal social services (PSS) perspective, over a cohort’s lifetime. RESULTS: The model base-case predicts that patients undergoing HNS will incur lifetime costs of £65,026 compared with £36,727 among untreated patients. The HNS cohort would gain 12.72 QALYs compared with 11.15 QALYs in the no-treatment arm. The ICER of treating severe OSAHS with HNS is therefore estimated to be £17,989 per QALYs gained. Probabilistic sensitivity analysis found that at a threshold of £30,000/QALY, HNS has a 69% probability of being cost effective. Limitations of the model include uncertainty around the utility data that were not sourced directly from HNS clinical trials. There is further uncertainty in the relationship between change in the Apnoea-Hypopnoea Index (AHI) and reduction in ischaemic heart disease and stroke because of difficulty capturing the reduction in risk over a long time horizon in studies. CONCLUSIONS: Over a patient’s lifetime, HNS with Inspire is expected to be cost effective when compared with no treatment in patients with severe OSAHS who have tried and have not responded to CPAP, from an NHS perspective. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-021-00266-7. Springer International Publishing 2021-04-28 /pmc/articles/PMC8333158/ /pubmed/33913119 http://dx.doi.org/10.1007/s41669-021-00266-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Blissett, Deirdre B.
Steier, Joerg S.
Karagama, Yakubu G.
Blissett, Rob S.
Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
title Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
title_full Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
title_fullStr Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
title_full_unstemmed Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
title_short Breathing Synchronised Hypoglossal Nerve Stimulation with Inspire for Untreated Severe Obstructive Sleep Apnoea/Hypopnoea Syndrome: A Simulated Cost-Utility Analysis from a National Health Service Perspective
title_sort breathing synchronised hypoglossal nerve stimulation with inspire for untreated severe obstructive sleep apnoea/hypopnoea syndrome: a simulated cost-utility analysis from a national health service perspective
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333158/
https://www.ncbi.nlm.nih.gov/pubmed/33913119
http://dx.doi.org/10.1007/s41669-021-00266-7
work_keys_str_mv AT blissettdeirdreb breathingsynchronisedhypoglossalnervestimulationwithinspireforuntreatedsevereobstructivesleepapnoeahypopnoeasyndromeasimulatedcostutilityanalysisfromanationalhealthserviceperspective
AT steierjoergs breathingsynchronisedhypoglossalnervestimulationwithinspireforuntreatedsevereobstructivesleepapnoeahypopnoeasyndromeasimulatedcostutilityanalysisfromanationalhealthserviceperspective
AT karagamayakubug breathingsynchronisedhypoglossalnervestimulationwithinspireforuntreatedsevereobstructivesleepapnoeahypopnoeasyndromeasimulatedcostutilityanalysisfromanationalhealthserviceperspective
AT blissettrobs breathingsynchronisedhypoglossalnervestimulationwithinspireforuntreatedsevereobstructivesleepapnoeahypopnoeasyndromeasimulatedcostutilityanalysisfromanationalhealthserviceperspective